<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5010">
  <stage>Registered</stage>
  <submitdate>25/03/2015</submitdate>
  <approvaldate>25/03/2015</approvaldate>
  <nctid>NCT02406989</nctid>
  <trial_identification>
    <studytitle>A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MS-553-102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Safety and PK in Healthy Volunteers</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MS-553
Treatment: drugs - Placebo

Experimental: MS-553 - MS-553 oral tablet BID x 14 days

Placebo Comparator: Placebo - Placebo oral tablet BID x 14 days


Treatment: drugs: MS-553
Study Drug

Treatment: drugs: Placebo
Matching placebo to MS-553

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Subjects with Adverse Events as a Measure of Safety and Tolerability</outcome>
      <timepoint>14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Peak Plasma Concentration (Cmax)</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the Plasma Concentration versus Time Area under the Plasma Concentration versus Time Curve</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  In good general health with BMI 18 to 32 kg/m2. Females must be nonpregnant,
             nonlactating, postmenopausal at least 2 years or surgically sterilized at least 6
             months prior</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History of skin rash, migraine, or clinically significant ocular diseases, conditions
             predisposing to QT prolongation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>32</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode>3122 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MingSight Pharmaceuticals Pty Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of
      MS-553 in healthy volunteers. Endpoints are safety, tolerability, and pharmacokinetics.
      Subjects are dosed for 14 days.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02406989</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>